REQUEST A DEMO
Total
USD $0.00
Search more companies

Steminent Biotherapeutics Inc. (Taiwan, China)

Main Activities: Research and Development in Nanotechnology
Full name: Steminent Biotherapeutics Inc. Profile Updated: January 28, 2026
Buy our report for this company USD 29.95 Most recent financial data: 2024 Available in: English & Chinese Download a sample report

Steminent Biotherapeutics Inc. is an enterprise in Taiwan, China, with the main office in Taipei City. The company operates in the Research and Development in Nanotechnology sector. The company was established on April 21, 2026. Over the same period, its total assets decreased by 25.33%.

Headquarters
No.16,Wenhu St,Neihu Dist
Taipei City; Taipei City;

Contact Details: Purchase the Steminent Biotherapeutics Inc. report to view the information.

Website: http://www.steminent.com

Basic Information
Outstanding Shares:
Purchase the Steminent Biotherapeutics Inc. report to view the information.
Financial Auditors:
Purchase the Steminent Biotherapeutics Inc. report to view the information.
Incorporation Date:
April 21, 2026
Key Executives
Purchase this report to view the information.
Chairman
Purchase this report to view the information.
Vice President
Ownership Details
Purchase this report to view the information.
4.27%
Purchase this report to view the information.
4.19%
Purchase this report to view the information.
4.09%
Purchase this report to view the information.
3.09%
Purchase this report to view the information.
2.78%
Subsidiaries
Steminent Inc (Samoa)
100%
Steminent Us, Inc (United States)
100%
Company Performance
Financial values in the chart are available after Steminent Biotherapeutics Inc. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency TWD. Absolute financial data is included in the purchased report.
Total Operating Revenue
-80%
Operating Profit
8.16%
EBITDA
18.73%
Net Profit/Loss for the Period
3.58%
Total Assets
-25.33%
Total Equity
-33.73%
Return on Equity (ROE)
-9.01%
Debt / Equity
13340%
Quick Ratio
-6087.21%
Cash Ratio
-7.31%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?